Takayuki Ohkuri

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 16

Top Venues

Cancer science

International journal of cancer

Cancer immunology, immunotherapy : CII

The Journal of experimental medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Ryosuke Sato, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. Cancer science 115 (4) (2024)
Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Ryosuke Sato, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. Cancer science (2024)
Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Ryosuke Sato, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. Cancer science 115 (4) (2024)
Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Ryosuke Sato, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. Cancer science 115 (4) (2024)
Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Ryosuke Sato, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. Cancer science 115 (4) (2024)
Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Ryosuke Sato, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. Cancer science 115 (4) (2024)
Hiroki Komatsuda, Risa Wakisaka, Michihisa Kono, Takumi Kumai, Ryusuke Hayashi, Hidekiyo Yamaki, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Miki Takahara, Akihiro Katada, Hiroya Kobayashi
Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation. Cancer science (2022)
Akemi Kosaka, Yuki Yajima, Shunsuke Yasuda, Hiroki Komatsuda, Toshihiro Nagato, Kensuke Oikawa, Hiroya Kobayashi, Takayuki Ohkuri
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 + T-cell functions via modulating glucose metabolism of CD11b + Ly6G + cells. International journal of cancer (2022)
Akemi Kosaka, Yuki Yajima, Shunsuke Yasuda, Hiroki Komatsuda, Toshihiro Nagato, Kensuke Oikawa, Hiroya Kobayashi, Takayuki Ohkuri
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 + T-cell functions via modulating glucose metabolism of CD11b + Ly6G + cells. International journal of cancer (2022)
Akemi Kosaka, Yuki Yajima, Shunsuke Yasuda, Hiroki Komatsuda, Toshihiro Nagato, Kensuke Oikawa, Hiroya Kobayashi, Takayuki Ohkuri
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 + T-cell functions via modulating glucose metabolism of CD11b + Ly6G + cells. International journal of cancer 152 (8) (2022)
Akemi Kosaka, Yuki Yajima, Shunsuke Yasuda, Hiroki Komatsuda, Toshihiro Nagato, Kensuke Oikawa, Hiroya Kobayashi, Takayuki Ohkuri
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 + T-cell functions via modulating glucose metabolism of CD11b + Ly6G + cells. International journal of cancer 152 (8) (2022)
Yuki Yajima, Akemi Kosaka, Kei Ishibashi, Shunsuke Yasuda, Hiroki Komatsuda, Toshihiro Nagato, Kensuke Oikawa, Masahiro Kitada, Masanori Takekawa, Takumi Kumai, Kenzo Ohara, Takayuki Ohkuri, Hiroya Kobayashi
A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity. Cancer science 113 (8) (2022)
Akemi Kosaka, Yuki Yajima, Shunsuke Yasuda, Hiroki Komatsuda, Toshihiro Nagato, Kensuke Oikawa, Hiroya Kobayashi, Takayuki Ohkuri
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 + T-cell functions via modulating glucose metabolism of CD11b + Ly6G + cells. International journal of cancer 152 (8) (2022)
Akemi Kosaka, Kei Ishibashi, Toshihiro Nagato, Hidemitsu Kitamura, Yukio Fujiwara, Syunsuke Yasuda, Marino Nagata, Shohei Harabuchi, Ryusuke Hayashi, Yuki Yajima, Kenzo Ohara, Takumi Kumai, Naoko Aoki, Yoshihiro Komohara, Kensuke Oikawa, Yasuaki Harabuchi, Masahiro Kitada, Hiroya Kobayashi, Takayuki Ohkuri
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. The Journal of experimental medicine 218 (11) (2021)
Marino Nagata, Akemi Kosaka, Yuki Yajima, Syunsuke Yasuda, Mizuho Ohara, Kenzo Ohara, Shohei Harabuchi, Ryusuke Hayashi, Hiroshi Funakoshi, Jun Ueda, Takumi Kumai, Toshihiro Nagato, Kensuke Oikawa, Yasuaki Harabuchi, Celis Esteban, Takayuki Ohkuri, Hiroya Kobayashi
A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. Cancer immunology, immunotherapy : CII 70 (8) (2021)
Akemi Kosaka, Yuki Yajima, Mayumi Hatayama, Katsuya Ikuta, Takaaki Sasaki, Noriko Hirai, Syunsuke Yasuda, Marino Nagata, Ryusuke Hayashi, Shohei Harabuchi, Kenzo Ohara, Mizuho Ohara, Takumi Kumai, Kei Ishibashi, Yui Hirata-Nozaki, Toshihiro Nagato, Kensuke Oikawa, Yasuaki Harabuchi, Esteban Celis, Toshikatsu Okumura, Yoshinobu Ohsaki, Hiroya Kobayashi, Takayuki Ohkuri
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. Cancer science 112 (7) (2021)

Takayuki Ohkuri.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Takayuki Ohkuri